| 12/11/2019 |
Consolidated Financial Results for the Second Quarter of the Fiscal Year Ending March 31, 2020 (IFRS) |
| 11/12/2019 |
FY2020/3 H1, Supplementary Material(Apr.1 to Sep.30 2019) |
| 11/12/2019 |
FY2020/3 H1, Presentation (Apr.1 to Sep.30 2019) |
| 09/30/2019 |
EISAI AND NICHI-IKO ENTER INTO COLLABORATION AGREEMENT FOR GENERIC PHARMACEUTICAL BUSINESS IN CHINA |
| 09/11/2019 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2020 (IFRS) |
| 09/05/2019 |
Sagent Pharmaceuticals Announces FDA Acceptance of Omega Manufacturing Site |
| 08/09/2019 |
Year Ending March 31, 2020 Results of 1stQuarterSettlement of Accounts Supplementary Material(Apr.1to Jun.30 2019) |
| 06/12/2019 |
Consolidated Financial Results for the Fiscal Year Ended March 31, 2019 (IFRS) |
| 06/03/2019 |
Notice of the 55th Ordinary General Meeting of Shareholders |
| 05/13/2019 |
The 8th Mid-term Business Plan |
| 05/13/2019 |
Year Ended March 31, 2019 Results Settlement of Accounts Supplementary Material (Apr.1 2018 to Mar.31 2019) |
| 05/13/2019 |
Cefazolin Sodium Details of Supply Issue |
| 05/13/2019 |
F2018, ended March 2019 |
| 04/01/2019 |
NICHI-IKO PHARMACEUTICAL AND EISAI COMMENCE CO-PROMOTION OF NICHI-IKO PRODUCTS AND COLLABORATION ON EISAI'S INTEGRATED PACKAGE STRATEGIES |
| 03/12/2019 |
Consolidated Financial Results for the third Quarter of the Fiscal Year Ending March 31, 2019 (IFRS) |
| 03/01/2019 |
Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site |
| 02/12/2019 |
FY2019/3 Q3, Supplementary Material(Apr.1 to Dec.31 2018) |
